Cisplatin Pfizer

Cisplatin

Monotherapy or in combination w/ other chemotherapeutic agents in the treatment of metastatic non-seminomatous germ cell carcinoma, advanced stage refractory ovarian/bladder carcinoma, refractory squamous cell carcinoma of the head & neck.

Adult & childn Monotherapy: 50-100 mg/m² as a single IV infusion every 3-4 wk over 6-8 hr or slow IV infusion of 15-20 mg/m²/day for 5 days every 3-4 wk. Combination therapy w/ the following cytotoxic agents: Testicular cancer Vinblastine, bleomycin, actinomycin D. Ovarian cancer Cyclophosphamide, doxorubicin, hexamethylmelamine, 5-fluorouracil. Head & neck cancer Bleomycin, methotrexate.

History of hypersensitivity to cisplatin or platinum-containing compd. Hearing disorders. Bone marrow depression. Renal impairment. Pregnancy & lactation.

Hydrate before, during & after therapy to minimise risk of nephrotoxicity. Monitor renal function including GFR, BUN, serum creatinine & CrCl; electrolytes (to detect hypomagnesaemia or hypocalcaemia); auditory function; RBC, WBC & platelets; liver function & neurological status prior to initial therapy, then before subsequent doses. Cumulative & dose-related renal insufficiency. Myelosuppression; do not institute subsequent courses of therapy until platelets are present at levels >100,000/mm³ & white cells >4,000/mm³. Packed RBC transfusions may be necessary for severe anaemia. Coombs' +ve haemolytic anaemia; may increase haemolysis in sensitised individuals in further courses of therapy. Reduce dose or discontinue treatment if severe nausea & vomiting occurs. Cumulative ototoxicity. Hypomagnesaemia & hypocalcaemia. Cessation of therapy is recommended if peripheral neuropathy, postural hypotension, myasthenic syndromes, seizures & visual loss occur, especially after prolonged treatment. Carefully observe for possible anaphylactic-like reactions; patients w/ family history of atopy. Patients may experience heterogeneous venous thromboembolic events, MI, cerebrovascular accidents, thrombotic microangiopathy & cerebral arteritis; pulmonary embolism. Preexisting hepatic & renal dysfunction. Women of childbearing potential should use adequate contraception.

Severe nausea & vomiting; acute renal toxicity; mild bone marrow toxicity (w/ both leucopenia & thrombocytopenia), anaemia; anaphylactic & anaphylactic-like reactions (eg, flushing, facial oedema, wheezing, tachycardia & hypotension); unilateral or bilateral tinnitus &/or hearing loss; peripheral & autonomic neuropathy, seizures, slurred speech, loss of taste & memory, CVA; retinal toxicity (eg, blurred vision & altered colour perception; CV abnormalities (coronary disease, CHF, arrhythmias, postural hypotension, thrombotic microangiopathy); venous thromboembolism; pulmonary toxicity; mild & transient serum AST & ALT elevations; mild alopecia; myalgia; spermatogenesis & azoospermia impairment; hypomagnesaemia, hypocalcaemia, hypokalaemia, renal tubular dysfunction, hyperuricaemia, hyponatremia, syndrome of inappropriate antidiuretic hormone; pyrexia, local effects (eg, phlebitis, cellulitis & skin necrosis).

May exacerbate the nephrotoxic & ototoxic effects w/ aminoglycosides or loop diuretics. Do not use live vaccines. Black precipitate occurs w/ Al.

Cytotoxic Chemotherapy

L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

POM